Bristol-Myers Squibb Co to Acquire Karuna Therapeutics Inc-M&A Call Transcript
Welcome to the Bristol-Myers Squibb acquisition of Karuna Therapeutics Conference Call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Tim Power, Vice President of Investor Relations. Please go ahead.
Thank you, and good morning, everyone. Thanks for joining us today to discuss our planned acquisition of Karuna Therapeutics.
On the call with me with prepared remarks are Chris Boerner, our Chief Executive Officer; David Elkins, our Chief Financial Officer; Adam Lenkowsky, our Chief Commercialization Officer; and Samit Hirawat, our Chief Medical Officer and Head of Global Drug Development. We're also joined for the Q&A by Robert Plenge, Executive Vice President and Chief Research Officer; and Richard Hargreaves, Senior Vice President, Neuroscience Therapeutic Research Center.
As you'll note, we've posted slides to bms.com that you can follow along with for the discussion. But before we get going, I'll read
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |